Phenotypes associated with this allele
mortality/aging
|
|
• mice die at 11 weeks after treatment with pIpC with splenomegalia and hepatomegalia
|
hematopoietic system
|
N |
• the deficits in splenocytes, bone marrow cells and pre-B cells observed in Rnf2tm1Mvi/Rnf2tm1Mvi Tg(Mx1-cre)1Cgn mice treated with pIpC at 6 to 12 weeks is not observed
|
|
|
• following treatment with pIpC at 6 to 12 weeks, mice exhibit an increase in myeloid colony forming units relative to wild-type mice
|
neoplasm
|
|
• following treatment with pIpC, mice develop lymphomas at an earlier age of onset compared to in Cdkn2atm1Rdp homozygotes
|
liver/biliary system
immune system
growth/size/body
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rnf2tm1Mvi mutation
(1 available);
any
Rnf2 mutation
(36 available)
Tg(Nes-cre/ERT2)5-1Imayo mutation
(1 available)
|
|
|
nervous system
|
|
• following exposure to tamoxifen at E13.5, the late-born/upper-layer neurons in the cortical plate at P6.5 that had been labeled with BrdU at E19.0 is greater than in control Rnf2tm1Mvi homozygotes
|
cellular
|
|
• following exposure to tamoxifen at E13.5, the late-born/upper-layer neurons in the cortical plate at P6.5 that had been labeled with BrdU at E19.0 is greater than in control Rnf2tm1Mvi homozygotes
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rnf2tm1Mvi mutation
(1 available);
any
Rnf2 mutation
(36 available)
Tg(Mx1-cre)1Cgn mutation
(7 available)
|
|
|
hematopoietic system
|
|
• when cells from a mouse treated with pIpC at 6 to 12 weeks where exposed to IL-7 in a clonogenic assay, the number and size of pre-B cell colonies is reduced compared to in wild-type mice
|
|
|
• following treatment with pIpC at 6 to 12 weeks, the progenitor compartment is enlarged and the number of hematopoietic stem cells is increased compared to in wild-type mice
|
|
|
• when cells from a mouse treated with pIpC at 6 to 12 weeks where exposed to IL-7 in a clonogenic assay, the number of myeloid colony forming units is increased 2-fold, all types of myeloid-derives cells are present at a 6-fold higher level, and granulo-mono-erythromegakaryocitic colonies are denser and contain a 5-fold increase in primitive common myeloid progenitors relative to in wild-type mice
|
|
|
• following treatment with pIpC at 6 to 12 weeks, the total number of bone marrow cells is nearly one third less than in wild-type mice
|
|
|
• following treatment with pIpC at 6 to 12 weeks, mice exhibit decreased erythrocyte numbers compared to in wild-type mice
|
|
|
• following treatment with pIpC at 6 to 12 weeks, some mice are thrombocytotic
|
|
|
• following treatment with pIpC at 6 to 12 weeks, the number of lymphoid B cells is slightly decreased compared to in wild-type mice
|
|
|
• following treatment with pIpC at 6 to 12 weeks, mice exhibit decreased splenocyte numbers compared to in wild-type mice
|
immune system
|
|
• when cells from a mouse treated with pIpC at 6 to 12 weeks where exposed to IL-7 in a clonogenic assay, the number and size of pre-B cell colonies is reduced compared to in wild-type mice
|
|
|
• following treatment with pIpC at 6 to 12 weeks, the number of lymphoid B cells is slightly decreased compared to in wild-type mice
|
|
|
• following treatment with pIpC at 6 to 12 weeks, mice exhibit decreased splenocyte numbers compared to in wild-type mice
|
hematopoietic system
|
|
• when cells are exposed to tamoxifen ex vivo, the progenitor compartment is increased compared to unexposed cells
|
|
|
• when cells are exposed to tamoxifen ex vivo, the number of myeloid colony forming units is increased compared to unexposed cells
• when cells are exposed to tamoxifen ex vivo, the proliferation of myeloid precursor cells is increased compared to unexposed cells
• however, myeloid cell apoptosis rates and differentiation are normal
|
|
|
• when cells are exposed to tamoxifen ex vivo, fewer pre-B cells are present compared to unexposed cells
|
immune system
|
|
• when cells are exposed to tamoxifen ex vivo, fewer pre-B cells are present compared to unexposed cells
|
nervous system
|
|
• E11.5 neural precursor cells cultured for 9 days in the presence of S33Y beta-catenin and tamoxifen exhibit enhanced neuronal differentiation compared with similarly treated control Rnf2tm1Mvi cells
• E17.5 neural precursor cells cultured for 3 days in the presence of S33Y beta-catenin and tamoxifen exhibit enhanced neuronal differentiation compared with similarly treated control Rnf2tm1Mvi cells
• neuronal precursor cells treated with tamoxifen and subjected to growth factor deprivation at the late stage (12 days in culture) exhibit reduced astrocyte differentiation compared with similarly treated control Rnf2tm1Mvi cells
• at P2.5, tamoxifen-treated mice exhibit reduced astrocytic differentiation compared with similarly treated control Rnf2tm1Mvi cells
|
cellular
|
|
• E11.5 neural precursor cells cultured for 9 days in the presence of S33Y beta-catenin and tamoxifen exhibit enhanced neuronal differentiation compared with similarly treated control Rnf2tm1Mvi cells
• E17.5 neural precursor cells cultured for 3 days in the presence of S33Y beta-catenin and tamoxifen exhibit enhanced neuronal differentiation compared with similarly treated control Rnf2tm1Mvi cells
• neuronal precursor cells treated with tamoxifen and subjected to growth factor deprivation at the late stage (12 days in culture) exhibit reduced astrocyte differentiation compared with similarly treated control Rnf2tm1Mvi cells
• at P2.5, tamoxifen-treated mice exhibit reduced astrocytic differentiation compared with similarly treated control Rnf2tm1Mvi cells
|
Analysis Tools